Subscribe
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.
Cannabidiol’s Approval on Dravet and Lennox-Gastaut Syndromes
Treatment Options and Patient Selection for Dravet and Lennox-Gastaut Syndromes
Heart Rate Variability’s Role in Potential SUDEP-Predicting Modalities: Orrin Devinsky, MD
Valproate, Regardless of Add-On Levetiracetam, Decreases Inflammatory Biomarker CCL2
Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD
Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA
James F. Howard Jr, MD, FAAN
Basil T. Darras, MD
Karissa Gable, MD
Anne M. Connolly, MD, FAAN; Amy Moore, PhD
Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP